Browse by Audience
Skip to content
Papers of the Week
Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis.
Abstract
The interleukin-22 cytokine (IL-22) has demonstrated efficacy in preclinical colitis models with non-immunosuppressive mechanism of action. Efmarodocokin alfa (UTTR1147A) is a fusion protein agonist that links IL-22 to the crystallisable fragment (Fc) of human IgG for improved pharmacokinetic characteristics, but with a mutation to minimise Fc effector functions.